Orna Therapeutics Announces Strategic Acquisition of ReNAgade Therapeutics to Solidify Leadership in Circular RNA Therapies
Orna Therapeutics Announces Strategic Acquisition of ReNAgade Therapeutics to Solidify Leadership in Circular RNA Therapies
Unifies World-Class Validated Circular RNA and Industry-leading Delivery Technologies to Advance New Category of panCAR in vivo CAR RNA Medicines for Oncology and Autoimmune Diseases
将世界一流的经过验证的环状核糖核酸和行业领先的递送技术相结合,推进用于肿瘤和自身免疫性疾病的新型PanCAR体内CAR RNA药物
Amit Munshi to Lead Company as Chief Executive Officer
阿米特·蒙希将领导公司担任首席执行官
Former Orna CEO Tom Barnes, Ph.D., to Remain on Board of Directors and Chair Scientific Advisory Board
Orna前首席执行官汤姆·巴恩斯博士将继续担任董事会成员兼科学顾问委员会主席
WATERTOWN and CAMBRIDGE, Mass., May 23, 2024 /PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA), today announced its acquisition of ReNAgade Therapeutics, a pioneer in unlocking the potential of RNA therapeutics that demonstrated industry-leading delivery to multiple extra-hepatic cells in non-human primate (NHP) models over the past 18 months.
马萨诸塞州沃特敦和剑桥,2024 年 5 月 23 日 /PRNewswire/ — Orna Therapeutics,一家致力于设计和交付全新一类全新环状核糖核糖核酸疗法 (orNA) 的生物技术公司),今天宣布收购RenaGade Therapeutics,这是释放RNA疗法潜力的先驱,在过去的18个月中,该疗法在非人灵长类动物(NHP)模型中向多个肝外细胞的输送业界领先。
Amit D. Munshi, Chief Executive Officer of ReNAgade, will succeed Tom Barnes, Ph.D., to lead Orna as Chief Executive Officer.
RenaGade首席执行官阿米特·蒙希将接替汤姆·巴恩斯博士领导奥纳担任首席执行官。
"RNA-centric approaches are poised to eclipse traditional cell therapy-based methods and reshape the future of medicine," said Mr. Munshi. "This strategic acquisition unifies Orna's and ReNAgade's strengths and capabilities under one roof, expanding technological synergies and multiplying the companies' depth and breadth of expertise to drive a unique RNA therapeutic-focused R&D engine. Orna will now advance an industry-leading approach combining the Company's circular RNA expression technology with ReNAgade's broad portfolio of LNP-based RNA delivery systems and comprehensive editing programs to solve the most pressing challenges in drug development."
蒙希说:“以RNA为中心的方法有望使基于细胞疗法的传统方法黯然失色,重塑医学的未来。”“此次战略收购将Orna和RenaGade的优势和能力统一在一个屋檐下,扩大了技术协同效应,使两家公司的专业知识深度和广度成倍增长,从而推动了以RNA疗法为重点的独特研发引擎。Orna现在将推进一种行业领先的方法,将公司的环状RNA表达技术与RenaGade广泛的基于LNP的RNA递送系统和全面的编辑程序组合相结合,以解决药物开发中最紧迫的挑战。”
An industry veteran of more than 30 years, Mr. Munshi is former President and CEO of Arena Pharmaceuticals Inc., which he built from a $300 million market cap into a late clinical stage company before its acquisition for $6.7 billion by Pfizer. Dr. Barnes will retain his position on Orna's Board of Directors and serve as chair of its Scientific Advisory Board.
作为30多年的行业资深人士,蒙希先生是Arena Pharmicals Inc. 的前总裁兼首席执行官。在辉瑞以67亿美元的价格收购Arena Pharmicals Inc.之前,他将该公司从3亿美元的市值发展成为一家处于临床后期阶段的公司。巴恩斯博士将继续在Orna董事会任职,并担任其科学顾问委员会主席。
"Orna remains singularly focused on developing the right tools and technologies and building the right company to power an entirely new class of RNA-based medicines," said Dr. Barnes, founding Chief Executive Officer of Orna Therapeutics. "The combination of technologies positions Orna to advance best-in-class panCAR in vivo CAR RNA therapies and expand existing gene editing delivery solutions with circular RNA to address the massive unmet need in multiple diseases."
Orna Therapeutics创始首席执行官巴恩斯博士表示:“Orna仍然专注于开发正确的工具和技术,建立合适的公司,为一种全新的基于RNA的药物提供支持。”“技术的结合使Orna能够推进同类最佳的PanCar的发展 在活体中 CAR RNA疗法,并使用环状RNA扩展现有的基因编辑交付解决方案,以满足多种疾病中未得到满足的巨大需求。”
"Both Orna and ReNAgade were founded on our bold vision to push the boundaries of RNA medicine," said Ansbert Gadicke, M.D., Managing Partner of MPM BioImpact. "The fusion of these industry leaders in circular RNA and delivery will transform the landscape of RNA therapeutics and accelerate clinical milestones leading to greater impact for patients living with cancer and autoimmune diseases. The combined company is supported by a substantial financial position enabling these milestones."
MPM BioImpact管理合伙人安斯伯特·加迪克医学博士表示:“Orna和RenaGade都建立在我们突破RNA医学界限的大胆愿景之上。”“这些行业领导者在环状核糖核酸和递送方面的融合将改变RNA疗法的格局,加快临床里程碑,从而对癌症和自身免疫性疾病患者产生更大的影响。合并后的公司得到了实现这些里程碑的充足财务状况的支持。”
Built by MPM BioImpact, both Orna and ReNAgade bring significant financing. Orna launched with $100 million in Series A financing in February 2021, subsequently announcing in August 2022 a $221 million Series B in addition to a strategic partnership. ReNAgade launched in May 2023 with $300 million Series A financing. The combined company will have a robust pipeline with panCAR programs in oncology and autoimmune disease, vaccine programs partnered with Merck, and genetic disease programs.
由MPM BioImpact建造,Orna和RenaGade都带来了大量融资。Orna于2021年2月启动了1亿美元的A轮融资,随后在2022年8月宣布了2.21亿美元的B轮融资,此外还建立了战略合作伙伴关系。RenaGade 于 2023 年 5 月推出,A 轮融资 3 亿美元。合并后的公司将拥有强大的产品线,包括肿瘤学和自身免疫性疾病领域的PanCar项目、与默沙东合作的疫苗计划以及遗传病项目。
About Orna Therapeutics
Orna Therapeutics was founded on research by Alex Wesselhoeft, Ph.D., and Daniel G. Anderson, Ph.D., from MIT. It is dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna's proprietary platform combines novel technology to design circular RNA transcripts that drive protein expression with validated and unique delivery solutions. oRNAhas many advantages over traditional mRNA approaches, including simplified production, improved formulatability, and superior protein expression – making it a highly disruptive, new class of RNA therapeutics with vast potential to change patients' lives. To learn more, visit and follow Orna Therapeutics on X and LinkedIn.
关于奥纳疗法
Orna Therapeutics由麻省理工学院的亚历克斯·韦塞尔霍夫特博士和丹尼尔·安德森博士的研究创立。它致力于设计和交付一类全新的完全工程化的环状核糖核酸 (orNA))有可能改变我们治疗疾病的方式的疗法。Orna 的专有平台结合了新技术,设计了环状 RNA 转录本,通过经过验证的独特递送解决方案推动蛋白质表达。orna与传统的mRNA方法相比具有许多优势,包括简化生产、提高配方能力和卓越的蛋白质表达,使其成为一种极具颠覆性的新型RNA疗法,具有改变患者生活的巨大潜力。要了解更多信息,请访问 然后继续关注 Orna Therapeutics X 和 领英。
About ReNAgade Therapeutics
ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. It combines novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines. To accelerate the future of medicine, ReNAgade brings together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.
关于 RenaGade 疗法
RenaGade的存在是为了释放RNA药物治疗人体任何部位疾病的潜力。它将新型的RNA递送平台与全面的RNA平台相结合,允许使用全RNA系统进行编码、编辑和基因插入,以开发新药。为了加速医学的未来,RenaGade召集了一支具有深厚RNA和交付专业知识的团队,开发可改变范式的RNA药物。
SOURCE Orna Therapeutics
来源 Orna Therapeutic